Results 161 to 170 of about 50,442 (246)
Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long +6 more
wiley +1 more source
Bivalent aptamer assemblies: A versatile toolkit for precision targeting of B-cell malignancies. [PDF]
Yin L.
europepmc +1 more source
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple +8 more
wiley +1 more source
Innovative gene engineering strategies to address tumor antigen escape in cell therapy. [PDF]
Chen Y, Niu S, Li YR, Yang L.
europepmc +1 more source
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta +12 more
wiley +1 more source
CAR T Cell Therapy for Rheumatoid Arthritis. [PDF]
Freeley M.
europepmc +1 more source
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese +12 more
wiley +1 more source
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. [PDF]
Wang N +15 more
europepmc +1 more source

